Scorpius Holdings Board Approves 1-For-200 Reverse Stock Split Of Common Stock

7/17/24 4:33:48 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $SCPX alert in real time by email

However, there can be no assurance that that the Reverse Stock Split will increase the Company's stock price sufficiently in order to meet any requirements and policies of the NYSE American.

The Reverse Stock Split will take legal effect at 11:01 P.M. Eastern Time on July 17, 2024, and the Company's Common Stock will open for trading on the OTC Markets on July 18, 2024, on a post-split basis, under the existing ticker symbol "SCPX" but with new CUSIP number 42237K508.

Get the next $SCPX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SCPX

Date	Price Target	Rating	Analyst

More analyst ratings

Scorpius Holdings Launches Scorpius Ventures to Support U.S. Biotech Innovation through Flexible Equity-Based Onshoring Model
DURHAM, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today announced the launch of Scorpius Ventures, a new business unit designed to support emerging biotech companies with a flexible American onshoring model. By combining service fees with an equity stake, Scorpius Ventures lowers financial barriers for its partners to onshore production of their biologics, creating a mutually beneficial pathway to accelerate biotech advancements. Scorpius Ventures' hybrid model offers capital-efficient access to its cGMP manufacturing services through in-kin
11/19/24 7:30:00 AM ET
$SCPX
Biotechnology: Pharmaceutical Preparations
Health Care
Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability
DURHAM, N.C., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today provided a strategic, financial, and operational update for the third quarter ended September 30, 2024. Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, "Scorpius continued to make strides in Q3, driven by key partnerships, disciplined financial management, and growth across our manufacturing and development services. We are proud to report a 142% year-over-year increase in revenue for the nine months ended September 30, 2024, reaching $5.2 million, which illustrates the demand fo
11/14/24 4:15:00 PM ET
$SCPX
Biotechnology: Pharmaceutical Preparations
Health Care
Scorpius Holdings Announces Collaboration with Celltheon Corporation, a U.S.-Based Cell Line Development Company; First Client Signed Under New Partnership Agreement
DURHAM, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today announced a partnership with Celltheon Corporation to provide cell line development services to clients using Celltheon's proprietary GOLDILOCKS™ transposase-based platform. This collaboration enables clients to integrate with Scorpius' program management team and quality system while preparing to transfer a research cell bank (RCB) to the Company's facilities in San Antonio, TX, for further biomanufacturing work. In addition to full-scale cell line development services, Celltheon offer
11/4/24 7:30:00 AM ET
$SCPX
Biotechnology: Pharmaceutical Preparations
Health Care

Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability
DURHAM, N.C., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today provided a strategic, financial, and operational update for the third quarter ended September 30, 2024. Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, "Scorpius continued to make strides in Q3, driven by key partnerships, disciplined financial management, and growth across our manufacturing and development services. We are proud to report a 142% year-over-year increase in revenue for the nine months ended September 30, 2024, reaching $5.2 million, which illustrates the demand fo
11/14/24 4:15:00 PM ET
$SCPX
Biotechnology: Pharmaceutical Preparations
Health Care
Scorpius Holdings Selected to Join Medical CBRN Defense Consortium to Advance Medical Countermeasures Against Chemical, Biological, Radiological, and Nuclear Threats
DURHAM, N.C., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today announced that it has been selected to join the Medical CBRN Defense Consortium (MCDC), a key organization advancing the development of medical countermeasures and related technologies to protect U.S. military personnel and civilians from chemical, biological, radiological, and nuclear (CBRN) threats. The MCDC, established in 2015 under the U.S. Department of Defense (DoD), serves as a collaborative framework for government, industry, and academia to partner on cutting-edge medical solu
10/2/24 8:00:00 AM ET
$SCPX
Biotechnology: Pharmaceutical Preparations
Health Care
Scorpius Holdings Appoints New VP of Business Development Shari Udoff-McDonald
DURHAM, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE:SCPX) ("Scorpius" or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced the appointment of Shari Udoff-McDonald as VP of Business Development. She brings more than 25 years of experience in biopharma business development and management. Prior to joining Scorpius, Ms. Udoff-McDonald spent 17 years at BioReliance Corporation, part of MilliporeSigma. She was most recently Head of Commercial, North America, East with interim oversight of half of the European market. Her role included commercial oversight of biologics, vaccines, cell and gene therapies, ADCs, and
5/7/24 8:30:00 AM ET
$SCPX
Biotechnology: Pharmaceutical Preparations
Health Care

Scorpius Holdings Board Approves 1-For-200 Reverse Stock Split Of Common Stock
However, there can be no assurance that that the Reverse Stock Split will increase the Company's stock price sufficiently in order to meet any requirements and policies of the NYSE American. The Reverse Stock Split will take legal effect at 11:01 P.M. Eastern Time on July 17, 2024, and the Company's Common Stock will open for trading on the OTC Markets on July 18, 2024, on a post-split basis, under the existing ticker symbol "SCPX" but with new CUSIP number 42237K508.
7/17/24 4:33:48 PM ET
$SCPX
Biotechnology: Pharmaceutical Preparations
Health Care
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Ovid Therapeutics Inc (NASDAQ:OVID) dipped 65.7% to $1.1285 after Takeda’s Skyline study in Dravet syndrome missed its primary endpoint. Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced topline data from its SKYLINE and SKYWAY Phase 3 studies of Soticlestat (TAK-935) for the treatment of Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS). AMMO shares dipped 19.1% to $2.0306 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Interactive Strength Inc. (NASDAQ:TRNR) shares climbed 148% to $7.07 after dipping 19% on Friday. Mustang Bio, Inc. (NASDAQ:MBIO) shares jumped 145% to $0.32 after the company announced safety and efficacy da
6/17/24 1:21:47 PM ET
$AAN
$AGRI
$ALLG
$AMCX
Diversified Commercial Services
Consumer Discretionary
Metal Fabrications
Industrials
US Stocks Mixed; Dow Tumbles Over 100 Points
U.S. stocks traded mixed this morning, with the Dow Jones index falling more than 100 points on Monday. Following the market opening Monday, the Dow traded down 0.34% to 38,456.60 while the NASDAQ rose 0.11% to 17,707.96. The S&P 500 also fell, dropping, 0.12% to 5,425.29. Check This Out: Top 4 Risk Off Stocks That May Rocket Higher In Q2 Leading and Lagging SectorsCommunication services shares jumped by 0.6% on Monday. In trading on Monday, industrials shares fell by 1%. Top Headline The NY Empire State Manufacturing Index rose to -6 in June versus a reading of -15.6 in May and coming in better than market expectations of -12.50. Equities Trading UP
6/17/24 9:40:41 AM ET
$ALLG
$AVTE
$MBIO
$OVID
Automotive Aftermarket
Consumer Discretionary
Biotechnology: Pharmaceutical Preparations
Health Care

Scorpius Holdings Board Approves 1-For-200 Reverse Stock Split Of Common Stock

Chat with this insight

Recent Analyst Ratings for
$SCPX

$SCPX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Wolf Jeffrey Alan was granted 2,500,000 shares (SEC Form 4)

$SCPX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Scorpius Holdings Inc.

SEC Form SC 13G filed by Scorpius Holdings Inc.

SEC Form SC 13D/A filed by Scorpius Holdings Inc. (Amendment)

$SCPX
Press Releases

Fastest customizable press release news feed in the world

$SCPX
Leadership Updates

Live Leadership Updates

Scorpius Holdings Launches Scorpius Ventures to Support U.S. Biotech Innovation through Flexible Equity-Based Onshoring Model

Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability

Scorpius Holdings Announces Collaboration with Celltheon Corporation, a U.S.-Based Cell Line Development Company; First Client Signed Under New Partnership Agreement

Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability

Scorpius Holdings Selected to Join Medical CBRN Defense Consortium to Advance Medical Countermeasures Against Chemical, Biological, Radiological, and Nuclear Threats

Scorpius Holdings Appoints New VP of Business Development Shari Udoff-McDonald

$SCPX
SEC Filings

SEC Form 10-Q filed by Scorpius Holdings Inc.

Scorpius Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Scorpius Holdings Inc. filed SEC Form 8-K: Financial Statements and Exhibits

$SCPX
Market Insights

Live Market Insights